Target Name: ENC1
NCBI ID: G8507
Review Report on ENC1 Target / Biomarker Content of Review Report on ENC1 Target / Biomarker
ENC1
Other Name(s): KLHL35 | nuclear restricted protein, BTB domain-like (brain) | OTTHUMP00000222056 | CCL28 | Nuclear matrix protein NRP/B | ectodermal-neural cortex 1 (with BTB-like domain) | KLHL37 | kelch-like protein 37 | Ectoderm-neural cortex protein 1 | NRPB | OTTHUMP00000222054 | kelch-like 35 | p53-induced gene 10 protein | tumor protein p53 inducible protein 10 | ENC-1 | PIG10 | Tumor protein p53 inducible protein 10 | kelch-like family member 37 | kelch-like 37 | Nuclear restricted protein, BTB domain-like (brain) | ENC1_HUMAN | nuclear matrix protein NRP/B | TP53I10 | ectodermal-neural cortex 1 | FLJ39259 | ENC1 variant 1 | Kelch-like protein 37 | Ectoderm-neural cortex protein 1 (isoform 1) | ectodermal-neural cortex 1 (with BTB domain) | Ectodermal-neural cortex 1, transcript variant 1

ENC1: A Protein Interacting with Heat Shock Factor

ENC1 (KLHL35) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and testes. It is a member of the heat shock protein (HSP) family, which are proteins that are expressed in response to increased levels of thermal stress in the cell.

One of the unique features of ENC1 is its ability to interact with other proteins, particularly with the protein known as heat shock factor (HSF). HSF is a protein that is also expressed in response to thermal stress and has been shown to play a role in the regulation of various cellular processes, including cell survival, metabolism, and stress responses.

Enc1 has been shown to be involved in a number of different cellular processes, including the regulation of protein synthesis and translation, DNA replication and repair, and stress responses. It has also been shown to play a role in the development and progression of various diseases , including cancer, neurodegenerative diseases, and autoimmune disorders.

As a drug target, ENC1 is being studied for its potential to intervene in a wide range of cellular processes and to treat a variety of diseases. For example, studies have shown that ENC1 can be targeted with small molecules and other therapeutic agents that can modulate its activity and improve its function in a variety of cellular contexts.

One of the key challenges in studying ENC1 is its complex structure and the fact that it is expressed in a wide variety of tissues and cells. This makes it difficult to study its effects in a specific context and to determine exactly how it interacts with other proteins . However, researchers are making progress in understanding the basic mechanisms that underlie ENC1's function and the ways in which it can be modulated.

Overall, ENC1 is a protein that is of great interest to researchers because of its potential role in the regulation of various cellular processes and its involvement in the development and progression of a wide variety of diseases. As more research is done on its mechanisms of action and potential therapeutic applications, it is likely to become an increasingly important target for the development of new treatments for a variety of diseases.

Protein Name: Ectodermal-neural Cortex 1

Functions: Actin-binding protein involved in the regulation of neuronal process formation and in differentiation of neural crest cells. Down-regulates transcription factor NF2L2/NRF2 by decreasing the rate of protein synthesis and not via a ubiquitin-mediated proteasomal degradation mechanism

The "ENC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV | ENG | ENGASE | ENHO | ENKD1 | ENKUR | ENO1 | ENO1-AS1 | ENO1P1 | ENO1P4 | ENO2 | ENO3 | ENO4 | ENOPH1 | eNoSC Complex | ENOSF1 | ENOX1 | ENOX1-AS2 | ENOX2 | ENPEP | ENPP1 | ENPP2 | ENPP3 | ENPP4 | ENPP5 | ENPP6 | ENPP7 | ENPP7P10 | ENPP7P12 | ENPP7P7 | ENSA | ENSAP2 | ENTHD1 | ENTPD1 | ENTPD1-AS1 | ENTPD2 | ENTPD3 | ENTPD3-AS1 | ENTPD4 | ENTPD5 | ENTPD6 | ENTPD7 | ENTPD8 | ENTR1 | ENTREP1 | ENTREP2 | ENTREP3 | env | ENY2 | EOGT | EOLA1 | EOLA1-DT | EOLA2 | EOLA2-DT | EOMES | EP300 | EP300-AS1 | EP400 | EP400P1 | EPAS1 | EPB41 | EPB41L1 | EPB41L1-AS1 | EPB41L2 | EPB41L3 | EPB41L4A | EPB41L4A-AS1 | EPB41L4A-DT | EPB41L4B | EPB41L5 | EPB42 | EPC1 | EPC2 | EPCAM | EPCAM-DT | EPDR1 | EPG5 | EPGN | EPHA1 | EPHA1-AS1 | EPHA10 | EPHA2 | EPHA2-AS1 | EPHA3 | EPHA4 | EPHA5 | EPHA5-AS1 | EPHA6 | EPHA7 | EPHA8